May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament The Health Care Blog Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As […]
May 19, 2011
By Andre Williams, Association of Black Cardiologists Politic365.com President Barack Obama recently indicated his interest in improving the Food and Drug Administration’s (FDA) approval process for new medical devices, saying the agency could “keep patients safer while getting innovative and life-saving products to market faster.” Read More
May 19, 2011
By Andre Williams, Association of Black Cardiologists Politic365.com President Barack Obama recently indicated his interest in improving the Food and Drug Administration’s (FDA) approval process for new medical devices, saying the agency could “keep patients safer while getting innovative and life-saving products to market faster.” Read More
May 10, 2011
Drugmakers seeking U.S. approval for the first lower-cost copies of biologic medicines made from living cells should initially pay application fees similar to charges for brand-name medicines, regulators said. Read More
April 24, 2011
Dr. Marcy L. Zwelling-Aamot Sacramento Bee When it comes to biologics, is biosimilar good enough? There is a new development in pharmaceuticals. It is a class of drugs called biologics. They are not only new; they are each unique. Read More
April 14, 2011
William P. Bro, Kidney Cancer Association At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney […]
April 14, 2011
William P. Bro, Kidney Cancer Association At the Kidney Cancer foundation we’re constantly seeking new ways to ensure those with cancer have access to the best medical data and medicines possible. For the past 20 years, we have served as a source of support and information for individuals and their loved ones affected by kidney […]
April 14, 2011
Tom Blackwell, National Post A growing tide of high-priced specialty medicines for arthritis, cancer and other diseases is set to put unprecedented pressure on workplace drug plans, likely forcing strict limits on what they cover, higher employee premiums and even an end to some plans altogether, experts are warning. Read more
February 16, 2011
Obtaining approval of new drugs can take as much money as $1 billion by the time research, manufacturing, safety and clinical trials have concluded. The pharmaceutical company patents the drug as soon as it is made, usually very early in the process of drug development. The patent protects that drug from being copied by anyone […]
February 16, 2011
Obtaining approval of new drugs can take as much money as $1 billion by the time research, manufacturing, safety and clinical trials have concluded. The pharmaceutical company patents the drug as soon as it is made, usually very early in the process of drug development. The patent protects that drug from being copied by anyone […]
